Navigation Links
Today's Technical View: AstraZeneca, GlaxoSmithKline, Keryx Biopharma, and Raptor Pharma

LONDON, July 11, 2013 /PRNewswire/ --

On Wednesday, July 10, 2013, shares in major drug manufacturers ended higher even as the broader market finished on a mixed note. The major movers in the industry included AstraZeneca Plc (ADR) (NYSE: AZN), GlaxoSmithKline Plc (ADR) (NYSE: GSK), Keryx Biopharmaceuticals (NASDAQ: KERX), and Raptor Pharmaceuticals Corp. (NASDAQ: RPTP). All these companies are tracked by Free in-depth technical analysis on AZN, GSK, KERX, and RPTP are currently available upon sign up at:  

Shares in AstraZeneca Plc edged higher on Wednesday, extending their gains for the week. The company's shares ended the day 0.78% higher at $48.94 after oscillating between $48.62 and $49.01. A total of 1.36 million shares were traded which is below the daily average volume of 1.95 million. The company's shares have gained 1.87% in the last three trading sessions as compared to a gain of 1.27% in the S&P 500. Sign up for free technical analysis on AZN at:

GlaxoSmithKline Plc's stock also extended its gains for the week on Wednesday. The company's shares fluctuated between $51.98 and $52.56 before finishing the day 1.26% higher at $52.29. A total of 1.66 million shares were traded which is below the daily average volume of 2.54 million. The company's shares have gained 2.13% so far this week and 9.51% in the last three months. The stock is currently trading near its 52-week high of $54.00. Download free report on GSK by registering at:

Shares in Keryx Biopharmaceuticals moved higher on Wednesday even as the broader market ended on a mixed note. The company's shares oscillated between $8.05 and $8.19 before ending the session 0.99% higher at $8.15. A total of 886,081 shares were traded which is less than its daily average volume of 2.36 million. Keryx's shares have gained 2.13% in the last three trading sessions, but have fallen 1.57% in the last three months. The free report on KERX can be downloaded by signing up now at:

Raptor Pharmaceuticals Corp.'s stock rose sharply on Wednesday, finishing at $10.36, up 6.26% from its previous closing price. The company's shares oscillated between $9.60 and $10.44. A total of 1.38 million shares were traded which is above the daily average volume of 637,187. The stock has gained 6.80% so far this week, and 81.12% in the last three months, compared to a gain of 1.27% and 4.09% in the S&P 500 in the respective periods. . A free report on RPTP can be accessed by registering at:



  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at
  5. For any urgent concerns or inquiries, please contact us at
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to for consideration.


Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.


Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.


Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

SOURCE AAA Research Reports
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Technical Briefing: Amgen, PDL BioPharma, Questcor Pharma, and BioCryst Pharma
2. Todays Technical View: Elan Corp., Amarin, Seattle Genetics, and Cubist Pharma
3. Invitation to Register: Annual Defense Threat Reduction Agency Basic Research Technical Review
4. BC Technical Acquires MEDX
5. Call for Papers for Pittcon 2014 Technical Program
6. Technical Workshops at OrthoTec 2013 Focus on Risk Management Throughout Medical Device Lifecycle and Robust Material Selection Process Development
7. Formedix to Host Webinar: Discover Define-XML - Practical Uses Today and a Technical Deep Dive on March 14, 2013
8. 20% Off Your Entire Order of Scientific, Technical, Medical (STM) Book Titles Until the End of March at Chemical Publishing Company
9. Technical Analysis on VIVUS and Achillion Pharma: Highlights on These Biotech Companies
10. Technical Analysis on GNC Holdings and Walgreen: Drug Store Stocks Set to Provide Good Returns
11. New England Biolabs New Website Adds Technical Information, Easy Ordering, and Better Search
Post Your Comments:
(Date:11/27/2015)... , November 27, 2015 ... Growing popularity of companion diagnostics is ... cancer biomarkers market with pharmaceutical companies and ... companion diagnostic tests. . ... Complete report on global cancer biomarkers ...
(Date:11/26/2015)... November 26, 2015 --> ... specializing in imaging technologies, announced today that it has received ... of the Horizon 2020 European Union Framework Programme for Research ... clinical trial in breast cancer. , --> ... --> --> The study aims ...
(Date:11/25/2015)... Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) ... a stockholder rights plan (Rights Plan) in an effort ... carryforwards (NOLs) under Section 382 of the Internal Revenue ... PharmAthene,s use of its NOLs could be substantially ... defined in Section 382 of the Code. In general, ...
(Date:11/25/2015)... , November 25, 2015 Studies ... and human plaque and pave the way for more effective ... in cats     --> ... commonly diagnosed health problems in cats, yet relatively little was ... Two collaborative studies have been conducted by researchers from the ...
Breaking Biology Technology:
(Date:11/12/2015)...  Arxspan has entered into an agreement with ... use of its ArxLab cloud-based suite of biological ... will support the institute,s efforts to electronically manage ... internally and with external collaborators. The ArxLab suite ... Institute,s electronic laboratory notebook, compound and assay registration, ...
(Date:11/10/2015)... Nov. 10, 2015 About ... that helps to identify and verify the identity ... considered as the secure and accurate method of ... a particular individual because each individual,s signature is ... especially when dynamic signature of an individual is ...
(Date:11/2/2015)... Nov. 2, 2015  SRI International has been awarded ... preclinical development services to the National Cancer Institute (NCI) ... provide scientific expertise, modern testing and support facilities, and ... pharmacology and toxicology studies to evaluate potential cancer prevention ... The PREVENT Cancer Drug Development Program is an NCI-supported ...
Breaking Biology News(10 mins):